Ligand Pharmaceuticals News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.12.24	Ligand Hosts 2024 Investor and Analyst Day and Introduces 2025 Guidance (Businesswire)
14.11.24	Ligand to Present at Stifel 2024 Healthcare Conference (Businesswire)
01.11.24	Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston (Businesswire)
23.10.24	Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024 (Businesswire)
06.09.24	Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy (Businesswire)
20.08.24	Ligand to Present at H.C. Wainwright 26th Annual Global Investment Conference (Businesswire)
23.07.24	Ligand to Report Second Quarter 2024 Financial Results on August 6, 2024 (Businesswire)
08.07.24	Ligand to Acquire APEIRON Biologics AG for $100 Million (Businesswire)
27.06.24	Ligand Partner Verona Pharma Announces FDA Approval of Ohtuvayre™ (ensifentrine), First Inhaled Novel Mechanism for Maintenance Treatment of COPD in More Than 20 Years (Businesswire)
18.06.24	Ligand Collaborator Merck Receives FDA Approval for CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Adults (Businesswire)
23.05.24	Ligand to Participate in Upcoming Investor Conferences (Businesswire)
07.05.24	Ligand Reports First Quarter 2024 Financial Results (Businesswire)
07.05.24	Ligand and Agenus Enter Into $100 Million Royalty Financing Agreement (Businesswire)
23.04.24	Ligand to Report First Quarter 2024 Financial Results on May 7, 2024 (Businesswire)
03.04.24	Ligand Pharmaceuticals Announces Launch of Pelthos Therapeutics to Accelerate Commercialization of ZELSUVMI™ (Businesswire)
05.03.24	Ligand Pharmaceuticals to Present at Barclays 26th Annual Global Healthcare Conference (Businesswire)
04.03.24	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
22.02.24	Ligand Partner Eisai Receives Approval in Japan for Injection Formulation of Antiepileptic Drug Fycompa® (Businesswire)
16.02.24	Ligand Pharmaceuticals Expands Senior Leadership Team with Two Key Hires (Businesswire)
13.02.24	Ligand to Report Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024 (Businesswire)
01.02.24	Ligand Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
05.01.24	U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum (Businesswire)
12.12.23	Ligand Holds Investor and Analyst Day; Provides Update on Portfolio Progress and Recent Transactions; Introduces 2024 Guidance (Businesswire)
06.12.23	Ligand to Host Investor and Analyst Day on December 12, 2023 in New York City (Businesswire)
08.11.23	Ligand Reports Third Quarter 2023 Financial Results (Businesswire)
01.11.23	Ligand Acquires Royalty on Sanofi’s TZIELD® for $20 Million (Businesswire)
25.10.23	Ligand To Report Third Quarter 2023 Financial Results On November 8 (Businesswire)
27.09.23	Ligand Acquires Assets of Novan, Inc. for $12.2 Million (Businesswire)
26.09.23	Ligand Appoints Martine Zimmermann to its Board of Directors (Businesswire)
18.09.23	Ligand Spins Out and Merges Pelican Subsidiary with Primordial Genetics to Form Primrose Bio (Businesswire)
02.09.23	Ligand Pharmaceuticals Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) (Businesswire)
08.08.23	Ligand Reports Second Quarter 2023 Financial Results (Businesswire)
25.07.23	Ligand To Report Second Quarter 2023 Financial Results On August 8 (Businesswire)
17.07.23	Ligand Offers $15 Million to Acquire Assets of Novan, Inc. (Businesswire)
16.05.23	Ligand’s Partner Viking Therapeutics Announces Positive Top-Line Results from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) (Businesswire)
04.05.23	Ligand Reports First Quarter 2023 Financial Results (Businesswire)
24.04.23	Ligand to Report First Quarter 2023 Financial Results on May 4, 2023 (Businesswire)
22.02.23	Ligand Reports Fourth Quarter and Full Year 2022 Financial Results (Businesswire)
06.02.23	Ligand to Report Fourth Quarter Financial Results on February 22 (Businesswire)
06.01.23	Ligand’s Partner Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum (Businesswire)
13.12.22	Ligand Provides Highlights from its Investor and Analyst Day Event (Businesswire)
05.12.22	Ligand Pharmaceuticals Names Director Todd C. Davis as CEO (Businesswire)
16.11.22	Ligand to Hold Investor and Analyst Day on December 13 (Businesswire)
07.11.22	Ligand Reports Third Quarter 2022 Financial Results (Businesswire)
01.11.22	Ligand Announces Completion of OmniAb Spin-Off (Businesswire)
01.11.22	Ligand Distribution of OmniAb Complete and Business Combination Closed (Businesswire)
27.10.22	Ligand to Report Third Quarter Financial Results on November 7 (Businesswire)
26.10.22	Ligand Announces that Janssen has Received Approval from U.S. FDA for TECVAYLI™ (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma (Businesswire)
24.10.22	OmniAb Business Combination Approved by APAC Shareholders (Businesswire)
03.10.22	Ligand Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	52.22	0.66 %	K V
Part Grp Hldg	1’274.00	0.55 %	K V
Holcim	89.08	0.25 %	K V
Kuehne+Nagel Int	202.90	0.15 %	K V
Alcon	76.40	0.10 %	K V
Swisscom	503.00	-0.79 %	K V
Swiss Re	130.65	-0.99 %	K V
Givaudan	4’014.00	-1.16 %	K V
Sika	223.50	-1.19 %	K V
Nestle	74.02	-1.60 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Ligand Pharmaceuticals Inc

Aktien Top/Flop

Meistgelesene Nachrichten